Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Adenocarcinoma × Heavy Ion Radiotherapy × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Pancreatic Neoplasms 6 Prostatic Neoplasms 4 Nasopharyngeal Carcinoma 3 Carcinoma, Hepatocellular 3 Sarcoma 2 Carcinoma 2 Vulvar Neoplasms 1 Uterine Cervical Neoplasms 1 Triple Negative Breast Neoplasms 1 Thymoma 1 Recurrence 1 Rectal Neoplasms 1 Radiation Injuries 1 Pancreatic Cancer Non-resectable 1 Ovarian Neoplasms 1 Osteosarcoma 1 Meningioma 1 Melanoma 1 Locally Advanced Pancreatic Cancer 1 Glioma 1 Chondrosarcoma 1 Carcinoma, Non-Small-Cell Lung 1 Breast Neoplasms 1 Adenocarcinoma 1

Interventions

Oxaliplatin 42 Gemcitabine 41 Fluorouracil 37 Capecitabine 29 pembrolizumab 28 Leucovorin 26 Docetaxel 25 Cisplatin 24 Paclitaxel 21 Carboplatin 18 Bevacizumab 17 Irinotecan 16 130-nm albumin-bound paclitaxel 16 Pemetrexed 15 Radiotherapy 13 Albumin-Bound Paclitaxel 13 Nivolumab 12 Cyclophosphamide 10 Ramucirumab 9 Trastuzumab 7 Radiosurgery 7 cemiplimab 6 Taxes 6 Erlotinib Hydrochloride 6 Drug Therapy 6 zolbetuximab 5 trastuzumab deruxtecan 5 durvalumab 5 Sorafenib 5 S 1 (combination) 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03536182 2021-05-26

CIPHER

University of Texas Southwestern Medical Center

Phase 3 Withdrawn

Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡